Novo Nordisk says 9,000 job cuts are nearly complete

Novo Nordisk has notified employees affected by its plan to cut 9,000 jobs in the vast majority of its locations, CEO Mike Doustdar said, though the pace of the notices varies from country to country because of local laws ^[1].

Doustdar announced the restructuring in September, and the reductions total 9,000 positions worldwide ^[1]. He described the progress in a post on LinkedIn on Friday, Oct. 31 ^[1].

The cuts come as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly, amid a race over weight-loss drugs ^[1].

Doustdar did not say which sites or countries have finished the process and which have not. He said only that employees in the vast majority of locations have been notified, and that local law sets the pace elsewhere ^[1].

Several basic details have not been reported: how many of the 9,000 roles have already ended, which departments or job types are included, what severance terms workers are receiving, and whether the total counts contractors or temporary staff ^[1]. It is also not known whether manufacturing sites, research operations, sales teams or patient support functions are affected ^[1]. Novo has not given a date for completing the remaining notifications ^[1].

Why it matters for patients

Novo Nordisk sells medicines in the U.S. market, where it competes with Eli Lilly ^[1]. The company has not said whether the restructuring changes anything about the products it sells, how quickly they are supplied, or what they cost ^[1].

For people who use Novo Nordisk medicines, the practical question is whether the jobs being removed sit close to the patient. Work that patients notice directly includes manufacturing, shipping, insurance and pharmacy paperwork, and help lines. Novo has not disclosed whether those areas are part of the 9,000 cuts, so it is not known whether people filling prescriptions or using company support programs will notice any change ^[1].

The restructuring also shrinks staff at a company competing for U.S. market share with Eli Lilly ^[1]. Novo has not said how, or whether, the job cuts are expected to affect the prices insurers and patients pay, or how its medicines reach pharmacies ^[1].

What happens next

Novo has not announced a completion date for the remaining notifications. Doustdar said the timing depends on local laws, which govern how and when employers can inform workers ^[1]. No other dated milestones have been disclosed ^[1].